Chronic dietary fat intake modifies the postprandial response of hemostatic markers to a single fatty test meal.
BACKGROUND
Hemostasis is the result of a complex equilibrium between coagulation and fibrinolysis, and the influence of different dietary models on this equilibrium is not entirely known.


OBJECTIVE
The objective was to compare the effects of the chronic intake of different dietary models on postprandial hemostasis.


METHODS
In a randomized crossover design, 20 healthy men consumed for 28 d each diets rich in monounsaturated fatty acids (MUFAs), saturated fatty acids (SFAs), and carbohydrates plus n-3 fatty acids (CHO/N3). Fasting and postprandial hemostatic factors (factor VII coagulant activity, plasminogen activator inhibitor-1, tissue-type plasminogen activator, d-dimer, and thromboxane B(2)) were measured; meal tests for the postprandial measures were based on butter, virgin olive oil, and walnuts for the SFA, MUFA, and CHO/N3 diets, respectively.


RESULTS
There were no differences in the fasting variables after the dietary periods. After the 3 fatty meals were consumed, we observed an increase in thromboxane B(2) and d-dimer and a reduction in tissue plasminogen activator, irrespective of the dietary model. The MUFA or CHO/N3 meals lowered postprandial concentrations of factor VII coagulant activity, although the reduction was greater after the MUFA-enriched meal. The concentration of plasminogen activator inhibitor-1 was greater after the SFA meal than after the other 2 meals.


CONCLUSIONS
The administration of a fatty meal induces a postprandial procoagulant tendency, irrespective of the type of fat consumed. However, the use of a dietary model rich in SFA creates a more procoagulant environment than does a model that includes MUFA or CHO/N3 as the source of fatty acids.
Delgado-Lista
Javier
J
Lipids and Atherosclerosis Research Unit, Reina Sofía University Hospital, Córdoba, and Ciber Fisiopatología Obesidad y Nutrición Instituto de Salud Carlos III, Spain.
Lopez-Miranda
Jose
J
Cortés
Begoña
B
Perez-Martinez
Pablo
P
Lozano
Aquiles
A
Gomez-Luna
Rafael
R
Gomez
Purificacion
P
Gomez
Maria Jose
MJ
Criado
Juan
J
Fuentes
Francisco
F
Perez-Jimenez
Francisco
F
D000328:Adult; D000933:Antifibrinolytic Agents / Q000097:blood; D015415:Biomarkers / Q000097:blood; D001777:Blood Coagulation; D018592:Cross-Over Studies; D004041:Dietary Fats / Q000008:administration & dosage*; D005167:Factor VII / Q000378:metabolism*; D005227:Fatty Acids / Q000008:administration & dosage; D005229:Fatty Acids, Monounsaturated / Q000008:administration & dosage; D015525:Fatty Acids, Omega-3 / Q000008:administration & dosage; D005231:Fatty Acids, Unsaturated / Q000008:administration & dosage; D005260:Female; D005338:Fibrin Fibrinogen Degradation Products / Q000378:metabolism*; D006487:Hemostasis; D006801:Humans; D008297:Male; D017395:Plasminogen Activator Inhibitor 1 / Q000097:blood*; D019518:Postprandial Period; D012016:Reference Values; D013929:Thromboxane B2 / Q000097:blood*; D010959:Tissue Plasminogen Activator / Q000097:blood*
D000933:Antifibrinolytic Agents; D015415:Biomarkers; D004041:Dietary Fats; D005227:Fatty Acids; D005229:Fatty Acids, Monounsaturated; D015525:Fatty Acids, Omega-3; D005231:Fatty Acids, Unsaturated; D005338:Fibrin Fibrinogen Degradation Products; D017395:Plasminogen Activator Inhibitor 1; C051321:SERPINE1 protein, human; C036309:fibrin fragment D; D013929:Thromboxane B2; D005167:Factor VII; D010959:Tissue Plasminogen Activator